Detection method of compound snow ginseng capsule
Through network pharmacological analysis and high-performance liquid chromatography detection, the active ingredient in compound Xuezan Capsules was determined and measured, which solved the problems of unknown efficacy and difficulty in quality control, and achieved effective quality control of BPH treatment drugs.
Patent Information
- Application Number
- CN202411016641.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-12
AI Technical Summary
Among the existing BPH treatment methods, there are complications in the surgery, and the side effects of drug treatment are large, and the medicinal substance basis of compound Xue Shen Capsules is unknown, and the quality standards are not comprehensive, making it difficult to effectively control the content of its drug-effective active ingredients.
The 10 pharmaceutically active ingredients of compound Xueguan Capsules were determined by network pharmacological analysis methods, and their content was determined by high-performance liquid chromatography detection method to provide quality control indicators.
The content of the medicinal active ingredients in the compound Xueguan capsule was accurately measured, ensuring product quality, providing effective quality control means, and supporting its application in BPH treatment.
Smart Images

Figure CN118937516A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug analysis, and particularly relates to a detection method for compound snow ginseng capsules. Background Art
[0002] Benign prostatic hyperplasia (BPH) is a common urological disease that causes urination disorders in middle-aged and elderly men. Statistics show that the incidence of BPH in men aged 60 is greater than 50%, and it reaches more than 80% at the age of 80. BPH is mainly manifested by histological hyperplasia of prostate stroma and glandular components, anatomical enlargement of the prostate, urodynamic bladder outlet obstruction and lower urinary tract symptoms (LUTS). The disease is characterized by frequent urination, urgency, and frequent urination at night, which seriously affects the patient's sleep quality and daily activities. Regarding the pathogenesis of BPH, there are several hypotheses in the discipline: autoimmune inflammation, urothelial integrity and functional defects, occult prostate infection, urination dysfunction, pelvic floor muscle spasm / pain, neuroendocrine disorders, peripheral / central nervous sensitization, neural remodeling, social and psychological conditions and genetic factors. Some researchers have also proposed that prostate microenvironment disorder, that is, local prostate microenvironment disorder caused by the combined effects of immune disorders, oxidative stress (OS), and pain factor release may be an important pathogenesis of BPH.
[0003] At present, the main treatments for BPH patients are surgical resection and drug therapy. Among them, surgical treatments include urethral plasma bipolar transurethral resection of the prostate (TUPKP) and urethral plasma enucleation of the prostate (TUKEP). Both surgical treatments have postoperative complications: urinary incontinence is about 1%-2.2%, retrograde ejaculation is about 65%-70%, and urethral stenosis is about 3.8%. Commonly used Western medicines for the treatment of BPH are α1-receptor blockers and 5α-reductase inhibitors. Among them, α1-receptor blockers are suitable for patients with prostatic hyperplasia with moderate to severe lower urinary tract symptoms. Commonly used drugs: doxazosin, terazosin, tamsulosin. 5α-reductase is a reductase that converts testosterone to dihydrotestosterone. Dihydrotestosterone has a certain role in benign prostatic hyperplasia. The use of 5α-reductase inhibitors can inhibit hyperplasia to a certain extent. Commonly used drugs are: finasteride and dutasteride. Common side effects of long-term use of this type of drug include dizziness, headache, fatigue, drowsiness, postural hypotension, abnormal ejaculation, etc. In view of the limitations of surgery itself and the side effects of existing drug treatments, Chinese patent medicine has become the preferred way to treat BPH.
[0004] Traditional Chinese medicine believes that this disease belongs to the category of "spermia", "urinary retention" and "stranguria syndrome". There are many records of stranguria in ancient Chinese medicine books. "Suwen·Wuchang Zhengdalun" states: "The disease of stranguria is caused by evil damaging the kidney." "Lingshu Jing·Benshu" says: "The triple burner... if it is full, it will cause stranguria, and if it is empty, it will cause nocturnal emission." "Suwen·Xuanming Wuqi" records: "Urinary bladder dysfunction is stranguria, and nocturnal emission." "Suwen·Biaobenbingchuanlun" believes that "bladder disease leads to urinary retention" (Zhang Chunhe, 2016). Traditional Chinese medicine believes that the etiology and pathogenesis of BPH are closely related to factors such as kidney deficiency and weak qi, blood stasis, dampness and heat. Traditional Chinese medicine emphasizes syndrome differentiation and treatment, and the treatment should be to activate blood circulation and remove blood stasis, promote dampness and relieve stranguria, and tonify the kidney. Developing and finding convenient, effective and low-toxic Chinese patent medicines is an urgent task for the treatment of BPH.
[0005] Compound Snow Ginseng Capsule is a clinically effective pure Chinese medicine compound preparation developed by the famous old Chinese medicine doctor Jia Kun based on Chinese medicine theory, experience and decades of clinical application. It is the first national new drug in my country to clearly treat prostatic hyperplasia. Previous clinical studies of the drug have also confirmed this indication. Compound Snow Ginseng Capsule is composed of 17 herbs, including Panax notoginseng, vinegar Trillium, vinegar Curcuma, Gleditsia sinensis, Zedoaria, Rhubarb, stir-fried Vaccaria, Polyporus, stir-fried Pharbitis, Epimedium, Hippophae rhizome, Polygonum cuspidatum, Paris polyphylla, Lysimachia chinensis, Smilax glabra, Taraxacum officinale, and Pheretima. It has the effects of promoting blood circulation and removing blood stasis, clearing heat and relieving stranguria. Compound Snow Ginseng Capsule has a clear clinical efficacy in the treatment of prostatic hyperplasia, but its material basis for efficacy is not clear, and the quality standards are not comprehensive. Summary of the invention
[0006] The purpose of the present invention is to provide a detection method for compound snow ginseng capsules. The detection method provided by the present invention determines the type of pharmacologically active ingredients of the compound snow ginseng capsules, and provides a detection method for the content of pharmacologically active ingredients of the compound snow ginseng capsules, which can be used as a quality control indicator of the compound snow ginseng capsules.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] The present invention provides a method for detecting compound snow ginseng capsules, comprising the following steps:
[0009] According to the effective chemical components of 17 traditional Chinese medicines constituting the compound snow ginseng capsule, a network pharmacology analysis method is used to obtain a network pharmacology map of the compound traditional Chinese medicine of the compound snow ginseng capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the compound snow ginseng capsule, 10 pharmacologically active ingredients of the compound snow ginseng capsule are obtained, and the 10 pharmacologically active ingredients are quercetin, luteolin, kaempferol, β-sitosterol, D-alanine-3-13C, stigmasterol, icariin, fisetin, acetylglycine and oxalic acid;
[0010] Extracting the compound snow ginseng capsule with a polar solvent, removing the solvent from the obtained extract to obtain a sample to be tested;
[0011] Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested;
[0012] The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients;
[0013] The conditions for the HPLC detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, and the procedure of the gradient elution is:
[0014] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 94 6 3.1 89.5 10.5 8.4 86.5 13.5 9.6 83 17 10.5 83 17 15.5 78.5 21.5 18.5 75 25 21 60 40 24 45 55 28 35 65 30 0 100 34 94 6 .
[0015] Preferably, the conditions for the HPLC detection also include: a column temperature of 32°C, a flow rate of the mobile phase of 1 mL min -1 .
[0016] Preferably, the conditions for the HPLC detection also include: a detection wavelength of 280 nm.
[0017] Preferably, the alcohol-water solvent for dissolving the sample to be tested is a methanol-water solution, and the mass percentage of methanol in the methanol-water solution is 80 wt %.
[0018] Preferably, in the liquid chromatography detection, the injection volume of the sample solution to be tested is 8 μL.
[0019] Preferably, the polar solvent used for the extraction is a low-carbon alcohol or a low-carbon alcohol aqueous solution, the low-carbon alcohol includes methanol or ethanol, and the low-carbon alcohol aqueous solution includes a methanol aqueous solution or an ethanol aqueous solution; the mass percentage of the low-carbon alcohol in the low-carbon alcohol aqueous solution is 80%.
[0020] Preferably, the solid-liquid ratio of the compound snow ginseng capsule and the polar solvent is 1:(15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions.
[0021] Preferably, the method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients comprises the following steps:
[0022] Dissolving 10 pharmacologically active ingredients and markers in alcohol-water solvents respectively, wherein the markers include one or more of phenol, hydroquinone, catechol and phloroglucinol, respectively obtaining a series of standard solutions of the 10 pharmacologically active ingredients and markers at different mass concentrations, respectively subjecting the 10 pharmacologically active ingredients and the standard solutions of the markers at different mass concentrations to high performance liquid chromatography detection, respectively obtaining a series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and markers, and obtaining liquid chromatographic retention times and linear ranges of the 10 pharmacologically active ingredients and markers from the series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and markers;
[0023] A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 10 pharmacologically active ingredients, a marker and an alcohol-water solvent, wherein the marker includes one or more of phenol, hydroquinone, catechol and phloroglucinol; a linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions and the liquid chromatographic retention times of the 10 pharmacologically active ingredients is obtained;
[0024] The linear regression equations of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution.
[0025] Preferably, the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution includes:
[0026] The linear regression equation of the mass concentration and peak area of D-alanine-3-13C is shown in Formula 1:
[0027] Y = 22450X + 5 Formula 1;
[0028] The linear regression equation of the mass concentration and peak area of the acetylglycine is shown in Formula 2:
[0029] Y = 11447X-10 Formula 2;
[0030] The linear regression equation of the mass concentration and peak area of the oxalic acid is shown in Formula 3:
[0031] Y = 10985X + 4 Formula 3;
[0032] The linear regression equation of the mass concentration and peak area of fisetin is shown in Formula 4:
[0033] Y = 11327X + 7 Formula 4;
[0034] The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 5:
[0035] Y = 12854X + 2 Formula 5;
[0036] The linear regression equation of the mass concentration and peak area of luteolin is shown in Formula 6:
[0037] Y = 14689X + 7 Formula 6;
[0038] The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 7:
[0039] Y = 14930X + 2 Formula 7;
[0040] The linear regression equation of the mass concentration and peak area of the β-sitosterol is shown in Formula 8:
[0041] Y = 18807X Formula 8;
[0042] The linear regression equation of the mass concentration and peak area of the stigmasterol is shown in Formula 9:
[0043] Y=2520.5X-4 Formula 9;
[0044] The linear regression equation of the mass concentration and peak area of the icariin is shown in Formula 10:
[0045] Y=9793.5X-6 Formula 10;
[0046] In formulas 1 to 10, X represents the mass concentration of D-alanine-3-13C, the mass concentration of acetylglycine, the mass concentration of oxalic acid, the mass concentration of fisetin, the mass concentration of quercetin, the mass concentration of luteolin, the mass concentration of kaempferol, the mass concentration of β-sitosterol, the mass concentration of stigmasterol, and the mass concentration of icariin in the mixed standard solution, respectively;
[0047] In Formulas 1 to 10: Y represents the peak area of D-alanine-3-13C, the peak area of acetylglycine, the peak area of oxalic acid, the peak area of fisetin, the peak area of quercetin, the peak area of luteolin, the peak area of kaempferol, the peak area of β-sitosterol, the peak area of stigmasterol, and the peak area of icariin in the liquid chromatogram of the mixed standard solution, respectively.
[0048] Preferably, the chromatographic column used in the HPLC has a length of 100 mm, an inner diameter of 4.6 mm, and a filler size of 1.8 μm.
[0049] The invention provides a detection method for compound snow ginseng capsules, comprising the following steps: according to the effective chemical components of 17 traditional Chinese medicines constituting the compound snow ginseng capsules, a network pharmacology analysis method is adopted to obtain a compound traditional Chinese medicine network pharmacology map of the compound snow ginseng capsules, and according to the compound traditional Chinese medicine network pharmacology map of the compound snow ginseng capsules, 10 pharmacologically active ingredients of the compound snow ginseng capsules are obtained, and the 10 pharmacologically active ingredients are quercetin, luteolin, kaempferol, β-sitosterol, D-alanine-3-13C, stigmasterol, icariin, fisetin, acetylglycine and oxalic acid; the compound snow ginseng capsules are extracted with a polar solvent, and the obtained extract is desolventized to obtain a sample to be tested; the sample to be tested is extracted with a polar solvent, and the solvent is removed from the obtained extract ... The method comprises the steps of: dissolving the mixture in an alcohol-water solvent to obtain a sample solution to be tested; performing high performance liquid chromatography on the sample solution to obtain a liquid chromatogram of the sample solution to be tested, and obtaining the peak areas corresponding to the 10 pharmacologically active ingredients in the compound snow ginseng capsule from the liquid chromatogram of the sample solution to be tested; and obtaining the mass contents of the 10 pharmacologically active ingredients in the compound snow ginseng capsule from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the 10 pharmacologically active ingredients; the conditions for the high performance liquid chromatography detection include: the mobile phase includes a mobile phase A and a mobile phase B, the mobile phase A is a 0.1 v:v% formic acid aqueous solution, and the mobile phase B is acetonitrile; and gradient elution is adopted, and the procedure of the gradient elution is as above. The detection method provided by the present invention adopts a network pharmacology analysis method to accurately determine 10 pharmacologically active ingredients of the compound snow ginseng capsule, and provides a high performance liquid chromatography detection method for the content of the pharmacologically active ingredients of the compound snow ginseng capsule. By controlling the detection conditions of the high performance liquid chromatography, the 10 pharmacologically active ingredients of the compound snow ginseng capsule can be accurately obtained, thereby being able to serve as quality control indicators of the compound snow ginseng capsule. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 This is the network pharmacology diagram of the compound snow ginseng capsule compound Chinese medicine. Figure 1 The squares are Chinese medicinal materials, the circles are ingredients, the diamonds are targets, and the hexagons are common ingredients;
[0051] Figure 2 is the liquid chromatogram of the mixed standard solution. Figure 2 1 represents D-alanine-3-13C; 2 represents acetylglycine; 3 represents oxalic acid; 4 represents fisetin; 5 represents phenol; 6 represents quercetin; 7 represents luteolin; 8 represents hydroquinone; 9 represents kaempferol; 10 represents β-sitosterol; 11 represents stigmasterol; 12 represents catechol; 13 represents epimedin; 14 represents phloroglucinol;
[0052] Figure 3 It is the liquid chromatogram of the sample solution to be tested. DETAILED DESCRIPTION
[0053] The present invention provides a method for detecting compound snow ginseng capsules, comprising the following steps:
[0054] According to the effective chemical components of 17 traditional Chinese medicines constituting the compound snow ginseng capsule, a network pharmacology analysis method is used to obtain a network pharmacology map of the compound traditional Chinese medicine of the compound snow ginseng capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the compound snow ginseng capsule, 10 pharmacologically active ingredients of the compound snow ginseng capsule are obtained, and the 10 pharmacologically active ingredients are quercetin, luteolin, kaempferol, β-sitosterol, D-alanine-3-13C, stigmasterol, icariin, fisetin, acetylglycine and oxalic acid;
[0055] Extracting the compound snow ginseng capsule with a polar solvent, removing the solvent from the obtained extract to obtain a sample to be tested;
[0056] Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested;
[0057] The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients;
[0058] The conditions for the HPLC detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, and the procedure of the gradient elution is:
[0059]
[0060]
[0061] In the present invention, unless otherwise specified, all preparation raw materials / components are commercially available products well known to those skilled in the art.
[0062] According to the effective chemical components of 17 traditional Chinese medicines constituting the compound snow ginseng capsule, the present invention adopts a network pharmacology analysis method to obtain a compound traditional Chinese medicine network pharmacology map of the compound snow ginseng capsule, and according to the compound traditional Chinese medicine network pharmacology map of the compound snow ginseng capsule, 10 pharmacologically active ingredients of the compound snow ginseng capsule are obtained, and the 10 pharmacologically active ingredients are quercetin, luteolin, kaempferol, β-sitosterol, D-alanine-3-13C, stigmasterol, icariin, fisetin, acetylglycine and oxalic acid.
[0063] In the present invention, the 17 Chinese medicinal herbs constituting the compound snow ginseng capsule include Panax notoginseng, vinegar-sweet Trillium, vinegar-sweet Curcuma, Gleditsia sinensis, Zedoaria, Rhubarb, stir-fried Vaccaria segetalis, Polyporus, stir-fried Pharbitis seeds, Epimedium, Hippophae rhizome, Polygonum cuspidatum, Paris polyphylla, Lysimachia chinensis, Smilax glabra, Taraxacum mongolicum and Pheretima.
[0064] In the present invention, the specific implementation method of obtaining the network pharmacology map of the compound traditional Chinese medicine of compound snow ginseng capsule by using the network pharmacology analysis method preferably includes:
[0065] 1. Collection and screening of active ingredients
[0066] The Chinese medicine systems pharmacology database analysis platform (TCMSP) was used to retrieve the effective chemical components of 17 Chinese medicines in Compound Snow Ginseng Capsule, and ADME parameters were used to screen out possible active drug molecules (the oral bioavailability threshold (OB) ≥ 30%, the drug similarity threshold (DL) ≥ 0.18%, and other parameters were set as default). The effective chemical components of Chinese medicines that could not be retrieved by TCMSP were screened by the Traditional Chinese Medicine Integrative Pharmacology Research Platform v2.0 (TCMIP) and literature. SwissADME was used for virtual screening of drug components and the intersection with BPH gene targets was taken, and 120 effective chemical components of Compound Snow Ginseng Capsule were obtained. Among them, there are 10 species of rhubarb, 14 species of earthworm, 3 species of Curcuma, 13 species of seahorse, 9 species of Polygonum cuspidatum, 10 species of Lysimachia chinensis, 11 species of Taraxacum, 12 species of Pharbitis nigra, 5 species of Trillium, 7 species of Panax notoginseng, 14 species of Smilax glabra, 4 species of Vaccaria segetalis, 21 species of Epimedium, 11 species of Gleditsia sinensis, 5 species of Eupatorium, 3 species of Paris polyphylla, and 5 species of Polyporus umbellatus. 27 ingredients are common to two or more medicinal materials.
[0067] 2. Prediction, screening and cross-validation of active ingredient target proteins
[0068] The TCMSP database was used to predict and screen 449 target proteins corresponding to 157 effective ingredients that met the criteria. The CTD database was used to search for related genes using prostatic hyperplasia as a keyword, and the genes ranked above 30 in the Inference score were intersected with the target proteins predicted by the TCMSP database, resulting in 237 intersection-related target proteins.
[0069] 3. GO functional annotation and KEGG pathway enrichment analysis
[0070] The 237 target proteins were analyzed by GO functional annotation and KEGG pathway enrichment in Metascape. GO functional annotation results showed that the target genes were involved in: positive regulation of cell death, regulation of apoptosis signaling pathways, regulation of hormone levels, regulation of small molecule metabolism, response to growth factors, transcription factor binding and protein phosphorylation. KEGG enrichment showed that these reaction processes may occur through pathways such as cell aging, chemical carcinogenesis, lipid and atherosclerosis, and cancer transcriptional dysregulation.
[0071] 4. Analysis of component-target protein interaction
[0072] The 237 target proteins obtained were uploaded to the STRING database for protein-protein interaction enrichment analysis. The species was set to "Homo sapiens", free nodes were hidden, and the minimum interaction requirement score was set to the highest confidence (0.900) for PPI network diagram construction. Cytoscape 3.9.1 was used to further analyze and optimize the PPI network diagram. A network interaction diagram consisting of 190 nodes and 979 edges was obtained (node size, color depth, and connection density represent the importance of target genes. The top 10 core genes with the highest degree values were: TP53, SRC, MAPK3, AKT1, MAPK1, RELA, CTNNB1, RXRA, ESR1, FOS and their interactions.
[0073] 5. Construction of network pharmacology of compound traditional Chinese medicine
[0074] The genes corresponding to the 237 target proteins obtained by screening were imported into Cytoscape 3.9.1 software to draw a network diagram of Chinese medicine compound, namely the "medicinal materials-ingredients-targets" network diagram. The network has a total of 374 nodes and 2623 relationships, including 17 drug nodes (Chinese medicinal materials), 120 chemical component nodes, and 237 target protein nodes of compound snow ginseng capsule. The top 10 chemical components with the highest degree values were analyzed as follows: quercetin (CAS: 117-39-5), luteolin (CAS: 491-70-3), kaempferol (CAS: 520-18-3), β-sitosterol (CAS: 83-46-5), D-alanine-3-13C (CAS: 133665-48-2), stigmasterol (CAS: 83-48-7), icariin (CAS: 118525-40-9), fisetin (CAS: 528-48-3), acetylglycine (CAS: 127883-08-3), and oxalic acid (CAS: 144-62-7). These components are the core control components of the efficacy of compound snow ginseng capsules.
[0075] The present invention extracts the compound snow ginseng capsule with a polar solvent, and obtains the sample to be tested after removing the solvent from the obtained extract. In the present invention, the polar solvent used for the extraction is preferably a low-carbon alcohol or a low-carbon alcohol aqueous solution, and the low-carbon alcohol preferably includes methanol or ethanol, and more preferably methanol. The low-carbon alcohol aqueous solution preferably includes a methanol aqueous solution or an ethanol aqueous solution, and more preferably an ethanol aqueous solution. The mass percentage of low-carbon alcohol in the low-carbon alcohol aqueous solution is preferably 80%. The solid-liquid ratio of the compound snow ginseng capsule and the polar solvent is preferably 1: (15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions. When the extraction is carried out under heating reflux conditions, the extraction time is preferably 3-4h, and the extraction is preferably carried out in a Soxhlet extractor. When the extraction is carried out under ultrasonic conditions, the number of extractions is preferably 2 times, and the time of each extraction is preferably 30-40min. The ultrasonic conditions include: the ultrasonic power is preferably 100-150W, and the ultrasonic frequency is preferably 40-50kHz. After the extraction, an extraction liquid is obtained, and the present invention preferably separates the extraction liquid into solid and liquid to obtain an extraction liquid. The solid-liquid separation is preferably carried out by filtration. The solvent removal is preferably carried out by evaporation. The solvent removal is preferably carried out in a rotary evaporator.
[0076] After obtaining the sample to be tested, the present invention dissolves the sample to be tested in an alcohol-water solvent to obtain a sample solution. As one or more embodiments of the present invention, the sample to be tested is dissolved in an alcohol-water solvent alone to obtain a sample solution; or the sample to be tested and the marker are dissolved in an alcohol-water solvent together to obtain a sample solution, at which time the sample solution contains the sample to be tested and the marker, and the marker includes one or more of phenol, hydroquinone, catechol and phloroglucinol, more preferably phenol, hydroquinone, catechol and phloroglucinol. In the present invention, the alcohol-water solvent for dissolving the sample to be tested is preferably a methanol aqueous solution, and the mass percentage of methanol in the methanol aqueous solution is preferably 80wt%. After the sample to be tested is dissolved in an alcohol-water solvent, an initial sample solution to be tested is obtained. The present invention preferably removes impurities from the initial sample solution to obtain the sample solution to be tested. The specific implementation of the removal of impurities is preferably membrane filtration, and the membrane filtration preferably uses a nylon membrane, and the pore size of the nylon membrane is preferably 0.22μm.
[0077] After obtaining the test sample solution, the present invention performs high performance liquid chromatography on the test sample solution to obtain a liquid chromatogram of the test sample solution, and obtains the peak areas corresponding to the 10 pharmacologically active ingredients in the compound snow ginseng capsule from the liquid chromatogram of the test sample solution; and then obtains the mass contents of the 10 pharmacologically active ingredients in the compound snow ginseng capsule from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the 10 pharmacologically active ingredients;
[0078] The conditions for the HPLC detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, and the procedure of the gradient elution is:
[0079]
[0080]
[0081] In the present invention, the meaning of the gradient elution procedure is:
[0082] From 0 min to 3.1 min, the volume percentage of mobile phase B changed linearly from 6% to 10.5%;
[0083] From 3.1 min to 8.4 min, the volume percentage of mobile phase B changed linearly from 10.5% to 13.5%;
[0084] From 8.4 min to 9.6 min, the volume percentage of mobile phase B changed linearly from 13.5% to 17%;
[0085] From 9.6 min to 10.5 min, the volume percentage of mobile phase B remained constant at 17%;
[0086] From 10.5 min to 15.5 min, the volume percentage of mobile phase B changed linearly from 17% to 21.5%;
[0087] From 15.5 min to 18.5 min, the volume percentage of mobile phase B changed linearly from 21.5% to 25%;
[0088] From 18.5 min to 21 min, the volume percentage of mobile phase B changed linearly from 25% to 40%;
[0089] From 21 min to 24 min, the volume percentage of mobile phase B changed linearly from 40% to 55%;
[0090] From 24 min to 28 min, the volume percentage of mobile phase B changed linearly from 55% to 65%;
[0091] From 28 min to 30 min, the volume percentage of mobile phase B changed linearly from 65% to 100%;
[0092] From 30 min to 34 min, the volume percentage of mobile phase B changed linearly from 100% to 6%.
[0093] In the present invention, the conditions for the HPLC detection preferably include: the column temperature is preferably 32°C, the flow rate of the mobile phase is preferably 1 mL·min -1 .
[0094] In the present invention, the conditions for the HPLC detection preferably also include: the detection wavelength is preferably 280 nm.
[0095] In the present invention, in the liquid chromatography detection, the injection volume of the sample solution to be tested is preferably 8 μL.
[0096] In the present invention, the chromatographic column used in the high performance liquid chromatography has a length of 100 mm, an inner diameter of 4.6 mm, and a filler size of 1.8 μm.
[0097] In the present invention, the method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients comprises the following steps:
[0098] Dissolving 10 pharmacologically active ingredients and markers in alcohol-water solvents respectively, wherein the markers include one or more of phenol, hydroquinone, catechol and phloroglucinol, respectively obtaining a series of standard solutions of the 10 pharmacologically active ingredients and markers at different mass concentrations, respectively subjecting the 10 pharmacologically active ingredients and the standard solutions of the markers at different mass concentrations to high performance liquid chromatography detection, respectively obtaining a series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and markers, and obtaining liquid chromatographic retention times and linear ranges of the 10 pharmacologically active ingredients and markers from the series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and markers;
[0099] A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 10 pharmacologically active ingredients, a marker and an alcohol-water solvent, wherein the marker includes one or more of phenol, hydroquinone, catechol and phloroglucinol; a linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions and the liquid chromatographic retention times of the 10 pharmacologically active ingredients is obtained;
[0100] The linear regression equations of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution.
[0101] In the present invention, the marker is preferably phenol, hydroquinone, catechol and phloroglucinol. When a series of standard solutions of 10 pharmacologically active ingredients and markers with different mass concentrations are subjected to HPLC detection, and a series of mixed standard solutions with different mass concentrations are subjected to HPLC detection, the HPLC detection method used is the same as the HPLC detection method of the sample solution to be tested in the above text, and will not be repeated here one by one.
[0102] In the present invention, the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution includes:
[0103] The linear regression equation of the mass concentration and peak area of D-alanine-3-13C is shown in Formula 1:
[0104] Y = 22450X + 5 Formula 1;
[0105] The linear regression equation of the mass concentration and peak area of the acetylglycine is shown in Formula 2:
[0106] Y = 11447X-10 Formula 2;
[0107] The linear regression equation of the mass concentration and peak area of the oxalic acid is shown in Formula 3:
[0108] Y = 10985X + 4 Formula 3;
[0109] The linear regression equation of the mass concentration and peak area of fisetin is shown in Formula 4:
[0110] Y = 11327X + 7 Formula 4;
[0111] The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 5:
[0112] Y = 1288547X + 2 Formula 5;
[0113] The linear regression equation of the mass concentration and peak area of luteolin is shown in Formula 6:
[0114] Y = 14689X + 7 Formula 6;
[0115] The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 7:
[0116] Y = 14930X + 2 Formula 7;
[0117] The linear regression equation of the mass concentration and peak area of the β-sitosterol is shown in Formula 8:
[0118] Y = 18807X Formula 8;
[0119] The linear regression equation of the mass concentration and peak area of the stigmasterol is shown in Formula 9:
[0120] Y=2520.5X-4 Formula 9;
[0121] The linear regression equation of the mass concentration and peak area of the icariin is shown in Formula 10:
[0122] Y=9793.5X-6 Formula 10;
[0123] In formulas 1 to 10, X represents the mass concentration of D-alanine-3-13C, the mass concentration of acetylglycine, the mass concentration of oxalic acid, the mass concentration of fisetin, the mass concentration of quercetin, the mass concentration of luteolin, the mass concentration of kaempferol, the mass concentration of β-sitosterol, the mass concentration of stigmasterol, and the mass concentration of icariin in the mixed standard solution, respectively;
[0124] In Formulas 1 to 10: Y represents the peak area of D-alanine-3-13C, the peak area of acetylglycine, the peak area of oxalic acid, the peak area of fisetin, the peak area of quercetin, the peak area of luteolin, the peak area of kaempferol, the peak area of β-sitosterol, the peak area of stigmasterol, and the peak area of icariin in the liquid chromatogram of the mixed standard solution, respectively.
[0125] In the present invention, the linear regression equations of mass concentration and peak area of 10 kinds of pharmacologically active ingredients and 4 kinds of markers in the mixed standard solution are shown in Table 1. In Table 1, 1 represents D-alanine-3-13C; 2 represents acetylglycine; 3 represents oxalic acid; 4 represents fisetin; 5 represents phenol; 6 represents quercetin; 7 represents luteolin; 8 represents hydroquinone; 9 represents kaempferol; 10 represents β-sitosterol; 11 represents stigmasterol; 12 represents catechol; 13 represents icariin; 14 represents phloroglucinol.
[0126] Table 1 Linear equations and linear ranges of 10 active ingredients and 4 markers
[0127]
[0128]
[0129] In order to further illustrate the present invention, the technical solutions provided by the present invention are described in detail below in conjunction with embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0130] Example 1
[0131] According to the effective chemical components of 17 traditional Chinese medicines constituting the compound snow ginseng capsule, the network pharmacology diagram of the compound traditional Chinese medicine of the compound snow ginseng capsule is obtained by the network pharmacology analysis method. According to the network pharmacology diagram of the compound traditional Chinese medicine of the compound snow ginseng capsule, 10 kinds of pharmacologically active ingredients of the compound snow ginseng capsule are obtained, and the 10 kinds of pharmacologically active ingredients are quercetin, luteolin, kaempferol, β-sitosterol, D-alanine-3-13C, stigmasterol, epimedin, fisetin, acetylglycine and oxalic acid. Among them, the 17 traditional Chinese medicines constituting the compound snow ginseng capsule include Panax notoginseng, vinegar triangularis, vinegar curcuma, Gleditsia sinensis, Zedoaria, rhubarb, stir-fried Vaccaria segetalis, Polyporus, stir-fried morning glory seeds, epimedium, hippocampus, Polygonum cuspidatum, Paris polyphylla, Lysimachia chinensis, Smilax glabra, Taraxacum mongolicum and Pheretima. In the embodiment, the specific implementation method of obtaining the network pharmacology map of the compound Chinese medicine of compound snow ginseng capsule by using the network pharmacology analysis method includes:
[0132] 1. Collection and screening of active ingredients
[0133] The Chinese medicine systems pharmacology database analysis platform (TCMSP) was used to retrieve the effective chemical components of 17 Chinese medicines in Compound Snow Ginseng Capsule, and ADME parameters were used to screen out possible active drug molecules (the oral bioavailability threshold (OB) ≥ 30%, the drug similarity threshold (DL) ≥ 0.18%, and other parameters were set as default). The effective chemical components of Chinese medicines that could not be retrieved by TCMSP were screened by the Traditional Chinese Medicine Integrative Pharmacology Research Platform v2.0 (TCMIP) and literature. SwissADME was used for virtual screening of drug components and the intersection with BPH gene targets was taken, and 120 effective chemical components of Compound Snow Ginseng Capsule were obtained. Among them, there are 10 species of rhubarb, 14 species of earthworm, 3 species of Curcuma, 13 species of seahorse, 9 species of Polygonum cuspidatum, 10 species of Lysimachia chinensis, 11 species of Taraxacum, 12 species of Pharbitis nigra, 5 species of Trillium, 7 species of Panax notoginseng, 14 species of Smilax glabra, 4 species of Vaccaria segetalis, 21 species of Epimedium, 11 species of Gleditsia sinensis, 5 species of Eupatorium, 3 species of Paris polyphylla, and 5 species of Polyporus umbellatus. 27 ingredients are common to two or more medicinal materials.
[0134] 2. Prediction, screening and cross-validation of active ingredient target proteins
[0135] The TCMSP database was used to predict and screen 449 target proteins corresponding to 157 effective ingredients that met the criteria. The CTD database was used to search for related genes using prostatic hyperplasia as a keyword, and the genes ranked above 30 in the Inference score were intersected with the target proteins predicted by the TCMSP database, resulting in 237 intersection-related target proteins.
[0136] 3. GO functional annotation and KEGG pathway enrichment analysis
[0137] The 237 target proteins were analyzed by GO functional annotation and KEGG pathway enrichment in Metascape. GO functional annotation results showed that the target genes were involved in: positive regulation of cell death, regulation of apoptosis signaling pathways, regulation of hormone levels, regulation of small molecule metabolism, response to growth factors, transcription factor binding and protein phosphorylation. KEGG enrichment showed that these reaction processes may occur through pathways such as cell aging, chemical carcinogenesis, lipid and atherosclerosis, and cancer transcriptional dysregulation.
[0138] 4. Analysis of component-target protein interaction
[0139] The 237 target proteins obtained were uploaded to the STRING database for protein-protein interaction enrichment analysis. The species was set to "Homo sapiens", free nodes were hidden, and the minimum interaction requirement score was set to the highest confidence (0.900) for PPI network diagram construction. Cytoscape 3.9.1 was used to further analyze and optimize the PPI network diagram. A network interaction diagram consisting of 190 nodes and 979 edges was obtained (node size, color depth, and connection density represent the importance of target genes. The top 10 core genes with the highest degree values were: TP53, SRC, MAPK3, AKT1, MAPK1, RELA, CTNNB1, RXRA, ESR1, FOS and their interactions.
[0140] 5. Construction of network pharmacology of compound traditional Chinese medicine
[0141] The genes corresponding to the 237 target proteins obtained by screening were imported into Cytoscape 3.9.1 software to draw a network diagram of Chinese medicine compound, namely the "medicinal materials-ingredients-targets" network diagram. The network has a total of 374 nodes and 2623 relationships, including 17 drug nodes (Chinese medicinal materials), 120 chemical component nodes, and 237 target protein nodes of compound snow ginseng capsule. The top 10 chemical components with the highest degree values were analyzed as follows: quercetin (CAS: 117-39-5), luteolin (CAS: 491-70-3), kaempferol (CAS: 520-18-3), β-sitosterol (CAS: 83-46-5), D-alanine-3-13C (CAS: 133665-48-2), stigmasterol (CAS: 83-48-7), icariin (CAS: 118525-40-9), fisetin (CAS: 528-48-3), acetylglycine (CAS: 127883-08-3), and oxalic acid (CAS: 144-62-7). These components are the core control components of the efficacy of compound snow ginseng capsules. The unique effective chemical components of the 17 Chinese medicinal materials in the compound snow ginseng capsule in this embodiment are shown in Table 2, and the common chemical components of the 17 Chinese medicinal materials in the compound snow ginseng capsule are shown in Table 3. The network pharmacology diagram of the compound Chinese medicinal materials of the compound snow ginseng capsule obtained in this embodiment is shown in Figure 1 As shown, Figure 1 The squares are Chinese medicinal materials, the circles are ingredients, the diamonds are targets, and the hexagons are common ingredients.
[0142] Table 2 Unique active chemical components from 17 medicinal materials in compound snow ginseng capsule
[0143]
[0144]
[0145] Table 3 Total chemical components of 17 medicinal materials in compound snow ginseng capsule
[0146]
[0147]
[0148] Standard preparation:
[0149] Prepare individual standard solutions for the 10 active ingredients and 4 markers (phenol, hydroquinone, catechol and phloroglucinol) of the compound snow ginseng capsule: accurately weigh a certain amount of standard substance (0.1-0.5 mg), add 5 mL of 80% methanol aqueous solution to a 10 mL volumetric flask, fully dissolve and dilute to 10 mL. When using, take 0.1 mL, 0.25 mL, 0.5 mL, 1 mL, and 2 mL of the mother solution of the standard solution and add them to a 10 mL volumetric flask, dilute to the scale with 80% methanol aqueous solution, and obtain 100, 75, 50, 10, and 5 times diluted standard solutions. Liquid chromatography retention time is qualitative, and peak area-concentration linear relationship analysis is quantitative.
[0150] Preparation of mixed standard solution: Take 0.1mL of each standard substance solution and marker solution of known concentration, add them to a 10mL volumetric flask, and dilute to the mark with 80% methanol aqueous solution to obtain a 100-fold diluted mixed standard substance solution (the mixed standard solution can be prepared in various concentrations and proportions according to the given method. The retention time obtained by a single standard substance is slightly different from the retention time obtained by the mixed standard substance, so the mixed standard substance spectrum is used to qualitatively and quantitatively analyze the sample). Use liquid chromatography to detect the 10 kinds of pharmacologically active ingredients in the mixed standard solution, and obtain the liquid chromatogram of the mixed standard solution, as shown in Figure 2. Figure 2 As shown, Figure 2 In Chinese: 1 represents D-alanine-3-13C; 2 represents acetylglycine; 3 represents oxalic acid; 4 represents fisetin; 5 represents phenol; 6 represents quercetin; 7 represents luteolin; 8 represents hydroquinone; 9 represents kaempferol; 10 represents β-sitosterol; 11 represents stigmasterol; 12 represents catechol; 13 represents icariin; 14 represents phloroglucinol.
[0151] A linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution is obtained from the mass concentration of the 10 pharmacologically active ingredients in the mixed standard solution, the liquid chromatogram of the mixed standard solution and the liquid chromatographic retention time of the 10 pharmacologically active ingredients; a linear regression equation of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution is obtained from the linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution. Details of the linear regression equation are shown in Table 1.
[0152] 15 g of compound snow ginseng capsules (commercially available product) were added to a 500 mL Soxhlet extractor, and an ethanol aqueous solution (wherein the mass percentage of ethanol was 80%) was added at a material-liquid mass ratio of 1:20, and the mixture was heated under reflux for 4 hours. The insoluble matter was removed by filtration, and the solvent was removed from the mixed solution by a rotary evaporator to obtain a sample to be tested.
[0153] The sample to be tested (0.1-0.5 mg) and four markers (phenol, hydroquinone, catechol and phloroglucinol, with masses of 0.1-0.5 mg respectively) were dissolved in 10 mL of 80 wt % methanol aqueous solution and filtered through a 0.22 m nylon membrane to obtain a sample solution to be tested.
[0154] After obtaining the sample solution to be tested, the sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, such as Figure 3 As shown, Figure 3 In the figure: 3 represents oxalic acid; 4 represents fisetin; 5 represents phenol; 6 represents quercetin; 9 represents kaempferol; 10 represents β-sitosterol; among them, since the contents of D-alanine-3-13C, acetylglycine, luteolin, stigmasterol, icariin and other markers in the test samples in this embodiment are low, they are difficult to identify with the naked eye, but the detector of high performance liquid chromatography can be used for qualitative and quantitative analysis.
[0155] The peak areas corresponding to the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass concentrations of the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from a linear fitting curve or a linear regression equation between the mass concentrations of the 10 pharmacologically active ingredients and the peak areas.
[0156] In the embodiment, the conditions of the above-mentioned high performance liquid chromatography detection are the same, including: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, the column temperature is preferably 32°C, and the flow rate of the mobile phase is preferably 1mL·min -1 The detection wavelength is preferably 280 nm, the injection volume of the sample solution to be tested is preferably 8 μL, the length of the chromatographic column used in the high performance liquid chromatography is 100 mm, the inner diameter is 4.6 mm, and the size of the filler is 1.8 μm. The procedure of the gradient elution is:
[0157] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 94 6 3.1 89.5 10.5 8.4 86.5 13.5 9.6 83 17 10.5 83 17 15.5 78.5 21.5 18.5 75 25 21 60 40 24 45 55 28 35 65 30 0 100 34 94 6 .
[0158] In this example, the contents of 10 core pharmacodynamic control components in the compound snow ginseng capsules were determined as (mg / g): D-alanine (0.0142), acetylglycine (0.0329), oxalic acid (0.0045), fisetin (0.0072), quercetin (0.0584), luteolin (0.0372), kaempferol (0.0822), β-sitosterol (0.1105), stigmasterol (0.0381), and icariin (0.0295).
[0159] Test Case
[0160] Activity analysis evaluation:
[0161] Preparation of the control substance of compound snow ginseng capsule: Take 10g of compound snow ginseng capsule powder, add 150mL of methanol, ultrasonically (power 100W, frequency 40kHz) for 30min, extract twice, and filter the solution under reduced pressure. Add 100mL of anhydrous ethanol to the filter residue, ultrasonically extract twice, and filter under reduced pressure. Combine the filtrate, condense and dry at room temperature, add 10mL of DMEM (high glucose culture medium) culture medium, and filter through a 0.22μm microporous filter membrane after ultrasonic dissolution to obtain a standard control solution, which is stored at -20℃ for use. When using, dilute it with DMEM culture medium to 0.5 times, 0.25 times, and 0.1 times the concentration of the control solution.
[0162] Preparation of drug equivalent solution: Take 10 core drug control components, weigh the sample according to the content level of each substance in 10 grams of original drug, add 10mL DMEM culture medium, and filter through 0.22μm microporous membrane after ultrasonic dissolution to obtain drug equivalent solution, and store at -20℃ for use. When using, dilute with DMEM culture medium to 0.5 times, 0.25 times, and 0.1 times the concentration of drug equivalent solution.
[0163] The control solution of compound snow ginseng capsule and its pharmacodynamic equivalent solution were used to treat dihydrotestosterone-induced WPMY-1 cells. The levels of PSA, DHT and E2 in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (954 (955) ng / ml, 5.5 (5.4) nM / L, 42.1 (42.2) pM / L). The NO content and NOS activity of WPMY-1 cells were detected by kit (6.2 (6.2) UM, 0.0053 (0.0054) Ug / ml). The protein expression levels of ERα, Bax, Bcl-2 and CyclinD1 in WPMY-1 cells were detected by Western Blot (0.68 (0.67), 1.57 (1.58), 0.46 (0.45), 0.21 (0.22)). The results showed that there were no significant differences in the parameters.
[0164] WPMY-1 cells induced by dihydrotestosterone were treated with 0.5 times control and 0.5 times drug equivalent solution of compound snow ginseng capsule. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (876 (870) ng / ml, 5.2 (5.3) nM / L, 41.5 (41.4) pM / L)). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.8 (5.8) UM, 0.0047 (0.0046) Ug / ml)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 in WPMY-1 cells were detected by protein immunoblot (Western Blot) (0.72 (0.72), 1.23 (1.22), 0.57 (0.56), 0.38 (0.39)). The results showed that there were no significant differences in the parameters.
[0165] WPMY-1 cells induced by dihydrotestosterone were treated with 0.25 times control and 0.25 times drug equivalent solution of compound snow ginseng capsule. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (752 (755) ng / ml, 5.0 (5.0) nM / L, 40.6 (40.5) pM / L). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.5 (5.5) UM, 0.0038 (0.0037) Ug / ml)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 in WPMY-1 cells were detected by Western Blot (0.77 (0.77), 1.05 (1.08), 0.82 (0.81), 0.75 (0.76)). The results showed that there were no significant differences in the parameters.
[0166] The 0.1-fold control and 0.1-fold drug equivalent solution of compound snow ginseng capsule were used to treat dihydrotestosterone-induced WPMY-1 cells. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (640 (645) ng / ml, 4.1 (4.2) nM / L, 39.8 (40.1) pM / L)). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.1 (5.1) UM, 0.0031 (0.0030) Ug / ml)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 in WPMY-1 cells were detected by Western Blot (0.85 (0.87), 0.82 (0.81), 0.93 (0.94), 0.88 (0.89)). The results showed that there were no significant differences in the parameters.
[0167] It can be seen from the above embodiments that the detection method provided by the present invention adopts the network pharmacology analysis method to accurately determine the 10 pharmacologically active ingredients of the compound snow ginseng capsule, and provides a high performance liquid chromatography detection method for the content of the pharmacologically active ingredients of the compound snow ginseng capsule. By controlling the detection conditions of the high performance liquid chromatography, the 10 pharmacologically active ingredients of the compound snow ginseng capsule can be accurately obtained, thereby being used as quality control indicators of the compound snow ginseng capsule.
[0168] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. Other embodiments can be obtained based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A method for detecting compound snow ginseng capsules, characterized in that: The following steps are involved: According to the effective chemical components of 17 traditional Chinese medicines constituting the compound snow ginseng capsule, a network pharmacology analysis method is used to obtain a network pharmacology map of the compound traditional Chinese medicine of the compound snow ginseng capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the compound snow ginseng capsule, 10 pharmacologically active ingredients of the compound snow ginseng capsule are obtained, and the 10 pharmacologically active ingredients are quercetin, luteolin, kaempferol, β-sitosterol, D-alanine-3-13C, stigmasterol, icariin, fisetin, acetylglycine and oxalic acid; Extracting the compound snow ginseng capsule with a polar solvent, removing the solvent from the obtained extract to obtain a sample to be tested; Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested; The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the 10 pharmacologically active ingredients in the compound snow ginseng capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients; The conditions for the high performance liquid chromatography detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; Gradient elution was used, and the procedure of the gradient elution was as follows: 。 2. The detection method according to claim 1, characterized in that: The conditions for the HPLC detection also include: column temperature of 32°C, flow rate of the mobile phase of 1 mL·min -1 .
3. The detection method according to claim 1 or 2, characterized in that: The conditions for the high performance liquid chromatography detection also include: the detection wavelength is 280nm.
4. The detection method according to claim 1, characterized in that: The alcohol-water solvent for dissolving the sample to be tested is a methanol-water solution, and the mass percentage of methanol in the methanol-water solution is 80wt%.
5. The detection method according to claim 1 or 4, characterized in that: In the liquid chromatography detection, the injection volume of the sample solution to be tested is 8 μL.
6. The detection method according to claim 1, characterized in that: The polar solvent used for the extraction is low-carbon alcohol or low-carbon alcohol aqueous solution, the low-carbon alcohol includes methanol or ethanol, and the low-carbon alcohol aqueous solution includes methanol aqueous solution or ethanol aqueous solution; the mass percentage of low-carbon alcohol in the low-carbon alcohol aqueous solution is 80%.
7. The detection method according to claim 1 or 6, characterized in that: The solid-liquid ratio of the compound snow ginseng capsule and the polar solvent is 1:(15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions.
8. The detection method according to claim 1, characterized in that: The method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients comprises the following steps: Dissolving 10 pharmacologically active ingredients and markers in alcohol-water solvents respectively, wherein the markers include one or more of phenol, hydroquinone, catechol and phloroglucinol, respectively obtaining a series of standard solutions of the 10 pharmacologically active ingredients and markers at different mass concentrations, respectively subjecting the 10 pharmacologically active ingredients and the standard solutions of the markers at different mass concentrations to high performance liquid chromatography detection, respectively obtaining a series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and markers, and obtaining liquid chromatographic retention times and linear ranges of the 10 pharmacologically active ingredients and markers from the series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and markers; A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 10 pharmacologically active ingredients, a marker and an alcohol-water solvent, wherein the marker includes one or more of phenol, hydroquinone, catechol and phloroglucinol; a linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions and the liquid chromatographic retention times of the 10 pharmacologically active ingredients is obtained; The linear regression equations of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution.
9. The detection method according to claim 1 or 8, characterized in that: The linear regression equations of mass concentration and peak area of the 10 kinds of active ingredients in the mixed standard solution include: The linear regression equation of the mass concentration and peak area of D-alanine-3-13C is shown in Formula 1: Y = 22450X + 5 Formula 1; The linear regression equation of the mass concentration and peak area of the acetylglycine is shown in Formula 2: Y = 11447X-10 Formula 2; The linear regression equation of the mass concentration and peak area of the oxalic acid is shown in Formula 3: Y = 10985X + 4 Formula 3; The linear regression equation of the mass concentration and peak area of fisetin is shown in Formula 4: Y = 11327X + 7 Formula 4; The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 5: Y = 12854X + 2 Formula 5; The linear regression equation of the mass concentration and peak area of luteolin is shown in Formula 6: Y = 14689X + 7 Formula 6; The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 7: Y = 14930X + 2 Formula 7; The linear regression equation of the mass concentration and peak area of the β-sitosterol is shown in Formula 8: Y = 18807X Formula 8; The linear regression equation of the mass concentration and peak area of the stigmasterol is shown in Formula 9: Y=2520.5X-4 Formula 9; The linear regression equation of the mass concentration and peak area of the icariin is shown in Formula 10: Y=9793.5X-6 Formula 10; In formulas 1 to 10, X represents the mass concentration of D-alanine-3-13C, the mass concentration of acetylglycine, the mass concentration of oxalic acid, the mass concentration of fisetin, the mass concentration of quercetin, the mass concentration of luteolin, the mass concentration of kaempferol, the mass concentration of β-sitosterol, the mass concentration of stigmasterol, and the mass concentration of icariin in the mixed standard solution, respectively; In Formulas 1 to 10: Y represents the peak area of D-alanine-3-13C, the peak area of acetylglycine, the peak area of oxalic acid, the peak area of fisetin, the peak area of quercetin, the peak area of luteolin, the peak area of kaempferol, the peak area of β-sitosterol, the peak area of stigmasterol, and the peak area of icariin in the liquid chromatogram of the mixed standard solution, respectively.
10. The detection method according to claim 1, characterized in that: The chromatographic column used in the high performance liquid chromatography has a length of 100 mm, an inner diameter of 4.6 mm, and a filler size of 1.8 μm.
